DK1896006T3 - Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet - Google Patents

Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet

Info

Publication number
DK1896006T3
DK1896006T3 DK06755404T DK06755404T DK1896006T3 DK 1896006 T3 DK1896006 T3 DK 1896006T3 DK 06755404 T DK06755404 T DK 06755404T DK 06755404 T DK06755404 T DK 06755404T DK 1896006 T3 DK1896006 T3 DK 1896006T3
Authority
DK
Denmark
Prior art keywords
entacapone
preparation
dosage form
oral dosage
containing granules
Prior art date
Application number
DK06755404T
Other languages
Danish (da)
English (en)
Inventor
Kari Vahervuo
Original Assignee
Orion Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37400847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1896006(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orion Corp filed Critical Orion Corp
Application granted granted Critical
Publication of DK1896006T3 publication Critical patent/DK1896006T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • A61K31/277Nitriles; Isonitriles having a ring, e.g. verapamil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/275Nitriles; Isonitriles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1641Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/2853Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK06755404T 2005-06-08 2006-06-07 Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet DK1896006T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68833405P 2005-06-08 2005-06-08
PCT/FI2006/000182 WO2006131591A2 (en) 2005-06-08 2006-06-07 An entacapone-containing oral dosage form

Publications (1)

Publication Number Publication Date
DK1896006T3 true DK1896006T3 (da) 2009-12-07

Family

ID=37400847

Family Applications (1)

Application Number Title Priority Date Filing Date
DK06755404T DK1896006T3 (da) 2005-06-08 2006-06-07 Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet

Country Status (19)

Country Link
US (3) US20080187590A1 (de)
EP (5) EP2316448A1 (de)
JP (2) JP5336181B2 (de)
KR (2) KR101617990B1 (de)
CN (1) CN101184483B (de)
AT (1) ATE444746T1 (de)
AU (1) AU2006256724B2 (de)
CA (1) CA2611114C (de)
CY (1) CY1109587T1 (de)
DE (1) DE602006009652D1 (de)
DK (1) DK1896006T3 (de)
EA (1) EA013161B1 (de)
ES (1) ES2311442T3 (de)
MX (1) MX2007015377A (de)
NO (1) NO345046B1 (de)
PL (1) PL1896006T3 (de)
PT (2) PT1896006E (de)
SI (1) SI1896006T1 (de)
WO (1) WO2006131591A2 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2429645A (en) * 2006-03-10 2007-03-07 Sekhsaria Chemicals Ltd Solid pharmaceutical composition comprising a COMT inhibitor, a starch and a wetting agent
US20100104634A1 (en) * 2006-12-27 2010-04-29 Mahesh Rameshwar Kalantri Pharmaceutical compositions of entacapone
EP1946756A1 (de) * 2007-01-17 2008-07-23 Revotar Biopharmaceuticals AG Verwendung von Entacapon für kosmetische, dermatologische und pharmazeutische Zusammensetzungen
ATE510537T1 (de) * 2008-02-06 2011-06-15 Wockhardt Research Center Pharmazeutische zusammensetzungen von entacapon, levodopa und carbidopa mit verbesserter bioverfügbarkeit
PT2293791E (pt) * 2008-02-06 2012-01-11 Wockhardt Ltd Composições farmacêuticas de entacapona co-micronizada com álcoois de açúcares
RU2540465C2 (ru) * 2008-08-22 2015-02-10 Вокхардт Рисерч Сентер Фармацевтическая композиция энтакапона или его солей пролонгрированного высвобождения
TR200806646A2 (tr) * 2008-09-03 2009-06-22 Dr. F. Fri̇k İlaç San. Ve Ti̇c. A.Ş. Entakapon, levodopa ve karbidoba içeren farmasötik kombinasyonlar
AU2011222856B2 (en) 2010-03-04 2015-10-15 Orion Corporation Use of levodopa, carbidopa and entacapone for treating Parkinson's disease
DE102010023828A1 (de) * 2010-06-15 2011-12-15 IIP - Institut für industrielle Pharmazie, Forschungs- und Entwicklungsgesellschaft mbH Pharmazeutisches Präparat, welches Entacapon, Levodopa und Carbidopa enthält
US8263119B2 (en) * 2010-12-01 2012-09-11 Shire Llc Capsule formulations containing lanthanum compounds
MX2013012429A (es) * 2011-04-26 2013-12-06 Innopharmax Inc Una composicion de entacopone.
CN103845318A (zh) * 2012-12-07 2014-06-11 天津市汉康医药生物技术有限公司 恩他卡朋分散片
PT2968218T (pt) * 2013-03-13 2021-09-24 Neuroderm Ltd Combinação para tratamento da doença de parkinson
KR102385603B1 (ko) * 2013-08-19 2022-04-11 타리스 바이오메디컬 엘엘씨 다중 유닛 약물 전달 장치 및 방법
US10258585B2 (en) 2014-03-13 2019-04-16 Neuroderm, Ltd. DOPA decarboxylase inhibitor compositions
ES2967693T3 (es) 2014-03-13 2024-05-03 Neuroderm Ltd Composiciones del inhibidor de la dopa descarboxilasa
JP2018500300A (ja) 2014-11-28 2018-01-11 ノヴィファーマ,エス.アー. パーキンソン病を遅延させるための医薬
JP6411265B2 (ja) * 2015-03-30 2018-10-24 共和薬品工業株式会社 エンタカポン含有医薬組成物
BR112017016393A2 (pt) * 2015-05-08 2018-03-27 Wockhardt Limited composições farmacêuticas estáveis compreendendo agente antibacteriano
WO2017028814A1 (en) * 2015-08-20 2017-02-23 Tsh Biopharm Corporation Ltd. Pharmaceutical composition comprising amlodipine and dextromethorphan
EP3275433A1 (de) * 2016-07-29 2018-01-31 Som Innovation Biotech S.L. Zusammensetzung mit verzögerter freisetzung mit mikronisiertem tolcapon
ES2895054T3 (es) * 2016-08-18 2022-02-17 Ilko Ilac Sanayi Ve Ticaret Anonim Sirketi Fórmula de comprimido antiparkinson con perfil de disolución mejorado
CN106236720A (zh) * 2016-08-29 2016-12-21 海南通用康力制药有限公司 一种恩他卡朋的药物组合物及其制备方法
TWI595871B (zh) * 2016-09-22 2017-08-21 生達化學製藥股份有限公司 含有兒茶酚-o-甲基轉移酶抑制劑之口服醫藥組成物及其製造方法
JP6735007B2 (ja) * 2018-09-26 2020-08-05 共和薬品工業株式会社 エンタカポン含有医薬組成物
AU2021235850A1 (en) * 2020-03-13 2022-10-06 BIAL - PORTELA & Cª, S.A. Micronised opicapone
US11844754B2 (en) 2020-11-17 2023-12-19 Neuroderm, Ltd. Methods for treatment of Parkinson's disease
US11213502B1 (en) 2020-11-17 2022-01-04 Neuroderm, Ltd. Method for treatment of parkinson's disease
US11331293B1 (en) 2020-11-17 2022-05-17 Neuroderm, Ltd. Method for treatment of Parkinson's disease
US20240300930A1 (en) * 2021-02-26 2024-09-12 Msn Laboratories Private Limited, R&D Center Novel process for the preparation of 2,5-dichloro-3-(5-(3,4-dihydroxy-5-nitrophenyl)-1,2,4-oxadiazol-3-yl)-4,6-dimethylpyridine-1-oxide
CN113274362A (zh) * 2021-03-31 2021-08-20 海南通用康力制药有限公司 恩他卡朋片的生产方法
US12161612B2 (en) 2023-04-14 2024-12-10 Neuroderm, Ltd. Methods and compositions for reducing symptoms of Parkinson's disease

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5283352A (en) 1986-11-28 1994-02-01 Orion-Yhtyma Oy Pharmacologically active compounds, methods for the preparation thereof and compositions containing the same
GB2238047B (en) 1989-11-03 1993-02-10 Orion Yhtymae Oy Stable polymorphic form of (e)-n,n-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide and the process for its preparation
US5429825A (en) * 1992-06-26 1995-07-04 Mcneil-Ppc, Inc. Rotomelt granulation
FI101039B (fi) * 1992-10-09 1998-04-15 Eeva Kristoffersson Menetelmä lääkepellettien valmistamiseksi
US5562291A (en) * 1995-09-28 1996-10-08 Daniel D. Garcia Arrow tip for shooting wooden target
US5952509A (en) * 1996-06-27 1999-09-14 Takeda Chemical Industries, Ltd. Production of benzaldehyde compounds
AU4078997A (en) * 1996-08-22 1998-03-06 New York University Cholinesterase inhibitors for treatment of parkinson's disease
US6599530B2 (en) * 1998-09-14 2003-07-29 Orion Corporation Oral compacted composition comprising catechol derivatives
US20080118556A1 (en) * 1998-11-02 2008-05-22 Elan Corporation, Plc Modified Release of Compositions Containing a Combination of Carbidopa, Levodopa and Entacapone
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
FI109453B (fi) * 1999-06-30 2002-08-15 Orion Yhtymae Oyj Farmaseuttinen koostumus
BR0307331A (pt) * 2002-02-01 2004-12-07 Pfizer Prod Inc Formulações granuladas a seco de azitromicina
US20040166159A1 (en) * 2002-05-29 2004-08-26 Chien-Hsuan Han Pharmaceutical dosage forms having immediate and controlled release properties that contain an aromatic amino acid decarboxylase inhibitor and levodopa
WO2005063696A2 (de) 2003-12-31 2005-07-14 Cilag Ag Neue kristalline formen von entacapone und deren herstellung
US20060222703A1 (en) * 2005-04-01 2006-10-05 Iprbox Oy Pharmaceutical composition and preparation method thereof
CA2635313C (en) * 2005-12-29 2013-12-31 Osmotica Corp. Triple combination release multi-layered tablet
US20090155369A1 (en) * 2007-12-13 2009-06-18 Laboratorios Lesvi, S.L. Pharmaceutical composition containing levodopa, entacapone and carbidopa

Also Published As

Publication number Publication date
JP2013173760A (ja) 2013-09-05
CY1109587T1 (el) 2014-08-13
NO345046B1 (no) 2020-09-07
CA2611114C (en) 2014-09-23
KR20080012945A (ko) 2008-02-12
NO20076687L (no) 2007-12-28
EA013161B1 (ru) 2010-02-26
DE602006009652D1 (de) 2009-11-19
EP2050447A1 (de) 2009-04-22
WO2006131591A3 (en) 2007-03-01
AU2006256724A1 (en) 2006-12-14
ES2311442T3 (es) 2010-01-07
KR101468738B1 (ko) 2014-12-03
EP1896006B1 (de) 2009-10-07
CA2611114A1 (en) 2006-12-14
MX2007015377A (es) 2008-02-14
EA200702616A1 (ru) 2008-04-28
US20080187590A1 (en) 2008-08-07
PT1896006E (pt) 2009-10-19
AU2006256724B2 (en) 2012-06-07
EP2316448A1 (de) 2011-05-04
US20120289594A1 (en) 2012-11-15
CN101184483A (zh) 2008-05-21
CN101184483B (zh) 2011-08-10
KR101617990B1 (ko) 2016-05-03
EP2308487A1 (de) 2011-04-13
JP5336181B2 (ja) 2013-11-06
JP2008542434A (ja) 2008-11-27
ATE444746T1 (de) 2009-10-15
SI1896006T1 (sl) 2010-02-26
EP2335696A1 (de) 2011-06-22
PL1896006T3 (pl) 2010-03-31
ES2311442T1 (es) 2009-02-16
KR20150001843A (ko) 2015-01-06
US20130274330A1 (en) 2013-10-17
EP2050447B1 (de) 2017-10-11
EP1896006A2 (de) 2008-03-12
WO2006131591A2 (en) 2006-12-14
PT2050447T (pt) 2018-01-17

Similar Documents

Publication Publication Date Title
DK1896006T3 (da) Fremstillingmetode for entacapon-holdige granuler til orale doseringsformet
LTPA2018010I1 (lt) Žmogaus anti-IL-23 antikūnai, kompozicijos, metodai ir panaudojimai
DK3851447T3 (da) Fremgangsmåder, forbindelser, sammensætninger og vehikler til administration af 3-amino-1-propansulfonsyre
CY1109916T1 (el) Βενζιμιδαζολο-θειοφαινικες ενωσεις ως plk αναστολεις
FR2883179B1 (fr) Comprime enrobe
PH12015500550A1 (en) Anti-notch1 nrr antibodies and methods using same
NO20070753L (no) Fremgangsmåte for fremstilling av dihydropteridinoner
ATE548374T1 (de) 2'-fluor-2'-desoxytetrahydrouridine als cytidindeaminaseinhibitoren
DK1893586T3 (da) Fremgangsmåde til fremstilling af 1-alkyl-3-phenyluraciler
ATE542823T1 (de) 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen
DK1877390T3 (da) Benzisoxazol-piperazin-forbindelser og fremgangsmåder til anvendelse deraf
DK1937633T3 (da) Biphenyloxyeddikesyrederivater til behandling af respiratoriske sygdomme
NO20055686L (no) Sammensetning, fremgangsmate til fremstilling derav, og anvendelse derav.
DK1817282T3 (da) Til behandling af respiratoriske sygdomme egnede phenoxy derivater
EA200970126A1 (ru) Способ получения прегабалина и его энантиомера
UA92894C2 (ru) Способ приготовления и применения композиции адсорбента фосфата, адсорбент фосфата, композиция адсорбента фосфата
DK1756049T3 (da) Fremgangsmåde til fremstilling af 1,4-diphenylazetidinon-derivater
ATE496913T1 (de) Neue, langwirksame betamimetika zur behandlung von atemwegserkrankungen
NO20060535L (no) Aztreonam-L-lysin og fremgangsmater for fremstilling av dette
DK1841433T3 (da) Præparat til behandling af lidelser i centralnervesystemet
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DK1831223T3 (da) Fremgangsmåde til fremstilling af L-biopterin
NO20091386L (no) Fenyloksyanilinderivater
DK1912961T3 (da) Fremgangsmåde til fremstilling af bepromolin
PL1853220T5 (pl) Sposób wytwarzania pastylek zawierających NLPZ, ich kompozycje, ich zastosowanie medyczne